What is Comprehensive genomic profiling
Comprehensive Genomic Profiling (CGP) using PGDx elio™ tissue complete is a next-generation sequencing (NGS)-based assay that analyzes formalin-fixed paraffin-embedded (FFPE) tumor tissue to identify a wide range of genomic alterations across 505+ cancer-associated genes. It is FDA-cleared and designed for use in CILIA-certified laboratories to guide precision oncology decisions.
WHY IT MATTERS FOR GLIOBLASTOMA PATIENTS
This test provides a comprehensive molecular portrait of the tumor, including:
- Single nucleotide variants (SNVs)
- Insertions and deletions (indels)
- Copy number alterations amplifications or deletions)
- Gene rearrangements (fusions)
- Tumor mutation burden (TMB)
- Microsatellite instability (MSI) status
This test yields a clinically-annotated report with relevant actionable alterations based on current evidence, including potential FDA-approved therapies, clinical trials, and prognostic biomarkers.
Molecular DIAGNOSIS
Helps provide a molecular diagnosis according to WHO 2021 Guidelines of IDH-wildtype glioblastoma.
"This test helped determine that my patient had IDH-wildtype glioblastoma with an actionable genomic alteration.”
- Provider using Comprehensive Genomic Profiling
Actionable genomic alterations in glioblastoma
Genomic alterations
FDA-approved targeted treatments
| FGFR2/3 | BALVERSA® (Erdafitinib) |
| BRAF V600 | TAFINLAR® (dabrafenib) |
| NF1 | MEKINIST® (trametinib) |
| NTRK | VITRAKVI® (larotrectinib) |
